Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 26 09 2018
accepted: 14 01 2019
pubmed: 24 5 2019
medline: 18 1 2020
entrez: 24 5 2019
Statut: ppublish

Résumé

To evaluate changes in macular vessel density following intravitreal anti-VEGF injection in patients with diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). In this retrospective case series, optical coherence tomography angiography (OCTA) images from 55 eyes of 35 patients with either DME (46 eyes) or PDR (9 eyes) were included. Macular capillary vessel density at the level of the superficial retinal capillary plexus (SCP), deep retinal capillary plexus (DCP) and total retinal capillary plexus (TCP) before and after anti-VEGF treatment was calculated. Longitudinal changes in vessel density following serial anti-VEGF treatment were analyzed in a subset of eyes. Vessel density in the SCP, DCP or TCP was not found to be significantly different after one, two or three intravitreal injections (p > 0.05 for all time points). Subgroup analysis revealed no significant change in the DME and PDR subgroups (all p > 0.05). Multivariate analysis revealed no effect of type of injected anti-VEGF agent or presence of previous treatment on VD measurements (all p > 0.05). There was no correlation between the anatomic response of DME to treatment and VD measurements. In this study, macular vessel density remained statistically unchanged following up to three intravitreal injections of any anti-VEGF agent. This indicates that there may not be an early effect of anti-VEGF treatment on macular vessel density and its effect on macular perfusion may not be a direct change in microvascular flow.

Identifiants

pubmed: 31119505
doi: 10.1007/s10792-019-01076-x
pii: 10.1007/s10792-019-01076-x
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Vascular Endothelial Growth Factor A 0
Bevacizumab 2S9ZZM9Q9V
Ranibizumab ZL1R02VT79

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2361-2371

Références

JAMA Ophthalmol. 2016 Apr;134(4):367-73
pubmed: 26795548
Ophthalmology. 1991 May;98(5 Suppl):786-806
pubmed: 2062513
Ophthalmic Surg Lasers Imaging. 2012 Jul 19;43 Online:e73-9
pubmed: 22823029
Diabetologia. 2008 Sep;51(9):1574-80
pubmed: 18404258
Retina. 2018 Jun;38(6):1238-1245
pubmed: 28613219
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):30-34
pubmed: 28114569
Br J Ophthalmol. 2010 Mar;94(3):381-3
pubmed: 20215378
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT362-70
pubmed: 27409494
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Int J Ophthalmol. 2017 Oct 18;10(10):1545-1551
pubmed: 29062774
JAMA Ophthalmol. 2013 Oct;131(10):1267-74
pubmed: 23907153
Retina. 2015 Nov;35(11):2364-70
pubmed: 26469537
Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):83-89
pubmed: 29082448
Retina. 2015 Nov;35(11):2353-63
pubmed: 26465617
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3907-13
pubmed: 27472076
Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):46-51
pubmed: 29436208
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):190-196
pubmed: 28114579
Int J Mol Sci. 2017 Jun 02;18(6):null
pubmed: 28574436
Am J Ophthalmol Case Rep. 2018 Jan 04;9:41-44
pubmed: 29468217
Am J Ophthalmol. 2016 May;165:133-44
pubmed: 26949134
Ophthalmol Retina. 2018 Mar;2(3):217-224
pubmed: 29527585
Ophthalmology. 2018 Oct;125(10):1568-1574
pubmed: 29752001
Ophthalmology. 2013 Apr;120(4):795-802
pubmed: 23260261
Ophthalmology. 2016 Nov;123(11):2368-2375
pubmed: 27613201
Ophthalmology. 2014 Sep;121(9):1783-9
pubmed: 24768239
Medicine (Baltimore). 2017 Nov;96(45):e8379
pubmed: 29137019
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140
pubmed: 28238195

Auteurs

Osama A Sorour (OA)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.
Ophthalmology Department, Tanta University, Tanta, Egypt.

Almyr S Sabrosa (AS)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.
Institute Ophthalmology Rio de Janeiro/Hospital da Gamboa, Rio de Janeiro, Brazil.

A Yasin Alibhai (A)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.

Malvika Arya (M)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.

Akihiro Ishibazawa (A)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.
Department of Ophthalmology, Asahikawa Medical University, Hokkaido, Japan.

Andre J Witkin (AJ)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.

Caroline R Baumal (CR)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.

Jay S Duker (JS)

New England Eye Center, Tufts Medical Center, Boston, MA, USA.

Nadia K Waheed (NK)

New England Eye Center, Tufts Medical Center, Boston, MA, USA. nwaheed@tuftsmedicalcenter.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH